Shengnuo Biotech (688117.SH) posted an advance increase. Net profit to mother is expected to increase by 43.23% to 64.79% year-on-year in the first half of the year

According to Zhitong Finance App News, Shengnuo Biotech (688117.SH) released its 2026 semi-annual performance forecast. It is expected to achieve net profit of 127 million yuan to 147 million yuan in the 2026 semi-year. Compared with the same period last year, it will increase 38.4573 million yuan to 57.638 million yuan, an increase of 43.23% to 64.79% over the previous year.

During the reporting period, the company closely focused on annual business goals, actively laid out its main business, and continued to expand domestic and foreign markets. Driven by this, the company's peptide API business is showing a continuous growth trend, driving a steady increase in the company's overall performance; secondly, thanks to the gradual release of the company's newly built production capacity, large-scale production effects and continuous optimization of production processes, effectively enhancing the company's overall profitability and further enhancing the company's global competitiveness in the peptide pharmaceutical market.